Sorafenib was the first RAF kinase inhibitor to enter human clinical trials in 1999. At that time the therapeutic hypothesis was that RAS mutant tumours could be treated by inhibiting a ‘druggable’ ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results